Earnest Partners LLC lessened its position in Catalent Inc (NYSE:CTLT) by 0.0% during the second quarter, Holdings Channel reports. The institutional investor owned 2,535,751 shares of the company’s stock after selling 199 shares during the quarter. Catalent makes up approximately 1.2% of Earnest Partners LLC’s investment portfolio, making the stock its 12th largest position. Earnest Partners LLC’s holdings in Catalent were worth $137,463,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of CTLT. Nordea Investment Management AB raised its position in shares of Catalent by 1.3% during the first quarter. Nordea Investment Management AB now owns 109,340 shares of the company’s stock worth $4,438,000 after purchasing an additional 1,350 shares during the period. Zions Bancorporation N.A. acquired a new stake in shares of Catalent during the first quarter worth $61,000. Westfield Capital Management Co. LP raised its position in shares of Catalent by 29.3% during the first quarter. Westfield Capital Management Co. LP now owns 448,946 shares of the company’s stock worth $18,223,000 after purchasing an additional 101,645 shares during the period. Bailard Inc. acquired a new stake in shares of Catalent during the second quarter worth $379,000. Finally, Lazard Asset Management LLC raised its position in shares of Catalent by 149.5% during the first quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock worth $30,085,000 after purchasing an additional 444,120 shares during the period.
Shares of Catalent stock opened at $51.95 on Friday. The company has a quick ratio of 1.70, a current ratio of 2.08 and a debt-to-equity ratio of 1.71. Catalent Inc has a twelve month low of $29.23 and a twelve month high of $58.38. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of 32.07, a P/E/G ratio of 2.46 and a beta of 1.65. The company’s fifty day moving average is $54.70 and its 200 day moving average is $48.42.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, August 27th. The company reported $0.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.03. Catalent had a net margin of 5.46% and a return on equity of 15.89%. The firm had revenue of $725.70 million during the quarter, compared to analyst estimates of $719.20 million. During the same quarter last year, the business posted $0.67 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. As a group, equities analysts anticipate that Catalent Inc will post 1.81 earnings per share for the current fiscal year.
In other Catalent news, SVP Steven L. Fasman sold 4,053 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $54.04, for a total value of $219,024.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Barry Littlejohns sold 15,940 shares of the firm’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $53.53, for a total transaction of $853,268.20. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
Several research analysts have recently issued reports on CTLT shares. Jefferies Financial Group upgraded Catalent from a “hold” rating to a “buy” rating and raised their price target for the stock from $50.00 to $62.00 in a research report on Friday, June 21st. Morgan Stanley raised their price objective on Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 28th. Robert W. Baird raised their price objective on Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. UBS Group lifted their price target on Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $57.14.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.